KLRA

$13.45-$0.30 (-2.18%)live

Compare

Change$-12.55

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Market cap

$1.8B

130M shares

52-week range

$13.32 – $28.23

1% from low

Sector

PHARMACEUTICAL PREPARATIONS

Exchange

NASDAQ

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2026	$0	—	$-4.62	$-5.91–$-3.63	—	4
2027	$0	—	$-4.62	$-6.09–$-3.09	—	4
2028	$0	—	$-4.36	$-6.99–$-2.14	—	6
2029	$67M	—	$-3.87	$-3.87–$-3.87	—	3

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 0 of the last 2 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-12	$-0.90	$-1.09	-21.6%
2026-05-26	$-0.78	$-3650.00	-470867.7%

DCF fair valuemodel estimate

Intrinsic value

$1.23

Price

$13.45

Implied downside

-91%

Kailera Therapeutics, Inc. Common Stock

Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.

www.kailera.com

IPO / List date: Apr 17, 2026
HQ: WALTHAM, MA

Held by traders on TradeandTell

No one on the platform currently holds KLRA.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in KLRA as of their last filing.

Insider activity (SEC Form 4)

Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded KLRA yet.

$KLRA chatter on StockTwits

John Balderson@JohnnyVacsBearish13h
$VKTX even the garbage $KLRA is about to be green 😂😂😂
View on StockTwits ↗
D.G.@DG202d
$VKTX $VKTX $NVO Novo’s data from UBT251 is mixed at best. It lacks the 3 qualities that makes VK2735’s data look so desirable. The weigh loss lines do NOT show proper dose response, they are far from monotonic (in A2 they are even jagged) and there appears to be a suggestion of deceleration of WL as time goes on… In fact, in ph1b 1mg did better than 3mg AND in ph2 4mg did better than 6mg????? NVO has no meaningful competitor for Tirzepatide (let alone Retatrutide) before the end of the decade IMO. Amylin also doubles GLP side effects to those who aren’t aware (ie Cagrisema/Amycretin). The CEO Doustdar clearly has a plan to close the gap with M&A activity. 👇👇👇👇 $KLRA is also a decent option but has a $5.7B overhang with Hangrui from China which also has 19.9% ownership of the company. NVO will acquire/partner for better assets (the company is strategically important to the Danish economy) and the next GLP/GIP dual agonist to market will be Vikings VK2735. DG20 StockTwits
View on StockTwits ↗
D.G.@DG204d
$KLRA $VKTX KLRA will absolutely have a place in the market but they potentially owe Hangrui over $5.7B in royalty payments so it’s not an easy acquisition for anyone. “Under the agreement, Hengrui received an upfront payment of $110 million, up to $200 million in clinical development and regulatory milestone payments, and up to $5.725 billion in sales milestone payments, while retaining a 19.9% equity stake in Kailera.” http://vcbeathealth.com/article/3046
View on StockTwits ↗
Biolover@bioloverBullish4d
$VKTX While novo is looking at everything. $KLRA SP action suggests lack of serious interest from novo or others prior to data maturing. KLRA is loaded with accounts and mgt that I am certain would have leaked and stopped the bleeding should have been a real interest at this point.
View on StockTwits ↗
D.G.@DG206d
$VKTX $NVO is the worlds largest pharmaceutical peptide developer and repeatedly the CEO has stated over the past year he is looking for a synergistic company to partner with or purchase to regain lost GLP market share. There is no way to know if it’s $KLRA or $VKTX as they are the two best late stage options but it’s almost certainly not going to be a small molecule developer like $GPCR as small molecules are not Novo’s strong suit…
View on StockTwits ↗
SpicyTrade@Spicy_TradeSep 2
Kailera Therapeutics, Inc. ( $KLRA ) SpicyTrade - Daily Stock Analysis https://youtu.be/B1hG93U7htU?si=cq8Ngt-VH1P7z7BT
View on StockTwits ↗
Victor Jade@vu_jadeSep 1
$KLRA Interesting
View on StockTwits ↗
HighRewards@HighRewardsAug 31
$KLRA Get some money back and load into RDHL its set to explode north go to X and type in RDHL stock is set to be over 8.00
View on StockTwits ↗
D.G.@DG20Aug 27
$NVO Novo will be fine after they acquire/partner with a company for a GIP dual agonist. Eventually they could combine with Cagrilinitide to create a triple agonist with better tolerability than Retatrutide. Until then PO Semaglutide is their only big gun and has patent protection issues. GIP is the only compound in late stage testing that improves tolerability of GLP medicines while also improving weight loss, A1C and MASH. $KLRA $VKTX are the best late stage options.
View on StockTwits ↗
Crosby Tao@GreenHawkzBearishAug 18
$VKTX even $KLRA has more volume than this thing. 22M shorts laughing in BL ‘s face 😂 $AMLX shareholders being rewarded nicely by good management who can actually produce results and talk properly.
View on StockTwits ↗
Biolover@bioloverBullishJul 30
$VKTX to be fair to the CEO , vanquish enrollment took 4.5 months for 4600 pts. The studios running well. Medpace is the CRO $KLRA enrollment for phase 3 ( smaller trials ) commenced Dec 2025 and has not finished yet. $GPCR has not started phase 3 yet.
View on StockTwits ↗
stockydennis@stockydennisBullishJul 29
$KLRA quiet 🤫
View on StockTwits ↗
stockydennis@stockydennisBullishJul 27
$KLRA ✊🏾
View on StockTwits ↗
stockydennis@stockydennisBullishJul 24
$KLRA $PFE glp-1 war
View on StockTwits ↗
John Balderson@JohnnyVacsBearishJul 24
$VKTX $KLRA & $GPCR catching up in market cap! Maybe BL can learn a couple things from them?
View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.